Last edition
News about "Angelini Pharma "
Angelini Pharma, Quiver Bioscience Ink USD 120 Million Pact to Develop Genetic Epilepsy Therapies
Angelini Pharma and Quiver Bioscience have signed a multi-year collaboration to develop novel therapies for genetic epilepsies, combining AI-driven discovery tools with epilepsy expertise in a deal worth up to USD 120 million.
Angelini Pharma | 25/02/2026 | By News Bureau
Helsinn Signs License Deal with Angelini Pharma to Commercialize AULIN and MESULID
Helsinn Group has signed Distribution and Licence Agreement renewal with Angelini Pharma in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic for AULIN and MESULID (Nimesulide) for the treatment of acute (short-term) pain.
Angelini Pharma | 29/05/2024 | By Aishwarya | 647
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy